GRAY SUSANNAH 4

What Happened

• Susannah Gray, a director of Theravance Biopharma, was granted two equity awards on June 12, 2026: an outright award of 6,009 shares and a derivative award covering 13,398 shares. Both grants are reported at $0.00 per share, so the filing shows no cash paid at grant (reported value $0).

Key Details

• Transaction date: 2026-06-12 (reported on Form 4 filed 2026-06-16).
• Transaction codes: A = Grant/Award. Reported prices: $0.00 for both the 6,009-share award and the 13,398-share derivative.
• Vesting/terms: Footnote F1 says the option vests 1/12th per month after the grant date; any remaining unvested shares vest on the next annual shareholders’ meeting if the director remains in continuous service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: Filing date (2026-06-16) is after the transaction date (2026-06-12); this appears to be a late Form 4 filing (transactionTimeliness = L).

Context

• This was a compensation grant to a director, not an open-market buy or sale. The 13,398-share item is a derivative option award that vests over time and may be exercised per the footnote; no immediate exercise or sale was reported. Director grants are common and are typically meant as compensation/retention rather than an immediate market signal.